Mounjaro prices to rise: what actually changes for patients

What actually happened to Mounjaro prices, and where they sit now

Eli Lilly's September 2025 list-price increase was substantial. Before it, the highest dose pen carried a list price of around £122; after, that figure moved to approximately £330, and you can read the full detail of what drove the Mounjaro price rise in September including the commercial context behind the change. Typical private market prices since then have ranged roughly £149 to £375 per month depending on the dose and the provider, figures reported widely at the time of the change and consistent with what patients have been quoting to our prescribers ever since.

The rise reflects Lilly's commercial decision as Mounjaro moved from a scarcity-managed launch into broader private supply. It does not affect the medicine itself: the same tirzepatide, the same KwikPen, the same licensed UK supply chain. But it does mean that anyone who started treatment at an earlier price point is now facing a meaningfully higher ongoing cost, and anyone weighing up starting has to do that maths with today's figures rather than last year's.

For context on the wider background to how Mounjaro is priced in the UK private market, the short version is that private pricing has always varied by dose and provider, and if you want a fuller picture of what the Mounjaro price rise involved and why it happened, that covers the timeline and the commercial reasoning behind it.

What headline prices often leave out, and why that changes the real comparison

When you see a monthly figure quoted for Mounjaro, it is worth asking what that number actually covers. Some providers include a consultation fee on top; others charge separately for the prescription, for dose-increase reviews, or for aftercare calls. Delivery costs can add up across a year. And ongoing clinical support (someone to contact if you feel unwell at a new dose, a prescriber who checks evidence before approving an increase) is either included or it is not.

This matters more after a price rise than before. When the headline figure was lower, a hidden £20 or £30 in extras felt marginal. At today's prices, a provider that looks £30 cheaper per month might reach the same annual figure once the full picture is on the table. The honest version of price comparison accounts for everything in the box, not just the pen.

Our breakdown of what Mounjaro pricing actually covers goes into this in more detail, including the clinical review steps that legitimate providers must carry out at every stage.

Where nume sits, and why we are not trying to be the cheapest option

We will be straightforward: cheapest is not a race we entered. The September 2025 price rise raised costs across the board, and if you want to understand the detail of how Mounjaro price rises have played out over time, the pattern shows a consistent direction of travel rather than a single unexpected event. We absorbed some of that pressure, but we did not respond by cutting corners on what is included.

One price at nume covers the consultation, the prescription, the medicine, and free next-working-day delivery via DPD, tracked, in plain packaging. It also covers clinical re-review before every repeat, aftercare seven days a week, and the same-day prescriber review that means if you order before noon on a weekday, a real clinician has read your answers before the school run ends. No bolt-on fees for dose-increase sign-off. No subscription trapping you into auto-renewal. If you want to check who is reviewing your treatment, our clinical team page is there.

Current treatment pricing is on our treatment page. We do not put per-pen prices in page copy, because the right dose for you depends on a clinical conversation, not a price list.

Why 'cheapest' is the wrong question for a prescription medicine

Tirzepatide is a Prescription-Only Medicine. Under UK law, a prescriber must assess your suitability (your BMI, your medical history, any medicines you take, any contraindications) before any supply is legal. The MHRA has been clear that GLP-1 medicines are not assessed for quick or cosmetic weight loss, and that patients should only obtain them through a proper clinical route.

That assessment costs something. It requires a qualified prescriber, a consultation system, pharmacy registration, all of it. A provider that is dramatically cheaper than the market is either omitting something from what you pay, or omitting something from what they do. The MHRA has seized around 20 million doses of illegally traded weight-loss medicines worth approximately £45 million, including counterfeit tirzepatide pens. Fake pens have no consistent active ingredient; some have contained insulin. The price reduction they offer is real; so is the risk.

You can verify any online pharmacy against the GPhC register at pharmacyregulation.org. Our GPhC premises registration number is 9012878. Sellers offering these medicines without a prescription (or with discount codes that seem too good to be true) are a red flag worth taking seriously.

For anyone weighing up the NHS route alongside private options, the picture on NHS access and costs is a useful starting point, and the broader weight-loss treatment overview sets out what both routes look like in practice.